How a University of Bristol spin-off grew to become the first lab customer at Future Space.
Pertinax Pharma were the first company to take up laboratory spaces here at Future Space. Pertinax is a patent-protected, sustained release technology for chlorhexidine, a common antiseptic. It can be used as a filler component of materials for biomedical and other applications, as a component of topical agents, and as a coating for medical devices.
"Moving our operation to Future Space offers us the opportunity to expand our team as we look to develop Pertinax for new applications and markets.”
Stuart Gibson, Chief Financial Officer for Pertinax Pharma
Dr Michele Barbour and her research group at the University of Bristol School of Oral and Dental Sciences have been developing sustained efficacy antimicrobial materials for many years. In April 2015 Pertinax Pharma Ltd was established to commercialise the many and diverse applications of this proprietary CHX technology. Since their ambitious move to Future Space here in Bristol, the company is looking to expand into different markets such as application of the product in wound care and veterinary markets.
More Case Studies
UWE interns adding value with Future Space companies
Learn about the UWE and Future Space internship programme giving students the opportunity to help solve real-life business issues faced by Future Space companies.
Company 500 more help Future Space customers develop their business
Learn how 500 More are helping Future Space companies bring their healthcare tech products and services to market more effectively.
How Future Space welcomed an esteemed robotics company to its list of pioneering science and technology companies […]